Business
SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa
Syndicate Bio to implement new liquid biopsy offering to advance cancer diagnostics throughout Africa BOSTON and ROLLE, Switzerland, April 23, 2024
About this update from Sophia Genetics Sa
[{"type":"text","content":"Syndicate Bio to implement new liquid biopsy offering to advance cancer diagnostics throughout Africa\nBOSTON and ROLLE, Switzerland, April 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDM™. Syndicate Bio is the first lab in Africa to adopt the MSK-ACCESS® assay via the SOPHiA DDM™ Platform, and the first company to make comprehensive genomic profiling and liquid biopsy widely available to patients throughout the entire continent. The implementation of this new technology will further existing work from SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center (MSK), and Syndicate Bio to advance health equity on a global scale.\n\n \n \n \n \n \n \n\n \nThere are roughly 1 million new cancer patients each year in Africa and currently, comprehensive genomic profiling and liquid biopsy testing options are not widely available. This means that patients are forced to forego this testing or travel out of continent for these testing options. Syndicate Bio's implementation of this new offering will provide cutting-edge liquid biopsy testing to many of these patients and will help progress the company's goal of advancing genomics and precision medicine in an area of the world that has been historically underserved in these areas.\n\"Partnering with SOPHiA Genetics to bring MSK-ACCESS® powered with SOPHiA DDM™ to our lab is a monumental step in accelerating the cancer treatment and research landscape across Africa, beginning in Nigeria. Next-generation sequencing technologies in oncology and liquid biopsy, which this collaboration enables, hold the potential for creating a leapfrogging opportunity in the oncology treatment and research landscape in Africa,\" said Abasi Ene-Obong, PhD., Founder, Syndicate Bio. \"Through this collaboration, we aim to enable the widespread application of precision medicine in oncology across Africa, and thus contributing to the improvement of patient outcomes across the African continent. We believe our scientific expertise, combined with AI-enabled technologies and data-driven solutions enabled by SOPHiA GENETICS, presents a unique opportunity to fundamentally transform the journey of cancer patien...